Glenmark Pharmaceuticals Ltd 532296
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Glenmark Pharmaceuticals Inaugurates U.S. Distribution Center in Allentown
Glenmark Pharmaceuticals and South Piedmont Community College Launch Aseptic Training Facility in Monroe, N.C.
Shares in Generic-Drug Makers Fall After Trump's Tariff Plan — Update
Shares in Generic-Drug Makers Fall After Trump's Tariff Plan
Trading Information
- Previous Close Price
- ₹2,675.00
- Day Range
- ₹2,635.40–2,680.45
- 52-Week Range
- ₹1,811.00–2,713.75
- Bid/Ask
- ₹0.00 / ₹0.00
- Shares Outstanding
- 282.22M
- Market Cap
- ₹749.43B
- Volume/Avg
- 16,643 / 24,516
Key Statistics
- Price/Earnings (Normalized)
- 43.49
- Price/Sales
- 4.80
- Dividend Yield (Trailing)
- 0.19%
- Dividend Yield (Forward)
- 0.19%
- Dividend Payment Schedule
- Sep
- Total Yield
- 0.19%
Company Profile
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Growth
- Total Number of Employees
- 16,946
Valuation
Metric | 532296 |
|---|---|
Price/Earnings (Normalized) | 43.49 |
Price/Book Value | 6.73 |
Price/Sales | 4.80 |
Price/Cash Flow | 33.12 |
Price/Earnings
532296
Financial Strength
Metric | 532296 |
|---|---|
Quick Ratio | 0.93 |
Current Ratio | 1.69 |
Interest Coverage | 10.43 |
Quick Ratio
532296
Profitability
Metric | 532296 |
|---|---|
Return on Assets (Normalized) | 7.41% |
Return on Equity (Normalized) | 14.30% |
Return on Invested Capital (Normalized) | 14.29% |
Return on Assets
532296
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|BylHj<< | LOCK|^$n>r | $74B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|cT@vg?> | LOCK|$Cnf | $50B | |||
| Haleon PLC ADR HLN | LOCK|Yk^@Dq | LOCK|w$@ | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|%Trt<z&$ | LOCK|@> | $34B | |||
| Viatris Inc VTRS | LOCK|$ds^W?^ | LOCK|%? | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|Vdz | LOCK|Mfg | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|FSlB&!< | LOCK|RCC | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|Z@&&C% | LOCK|rTJ | $5B | |||
| Perrigo Co PLC PRGO | LOCK|x<&qyy | LOCK|gL | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|>d?@z@ | LOCK|#yl> | $2B |
United States